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Somatostatin binding in normal and malignant human gastrointestinal
mucosa
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University Department ofSurgery, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Summary Somatostatin is a regulatory peptide implicated in the control of cellular proliferation in epithelial
tissues and this regulation may occur directly via membrane bound receptor activation. The aim of this study
was to investigate somatostatin binding in human gastrointestinal cancer and normal mucosa. Plasma
membranes were prepared from specimens of tumour and normal mucosa from 51 patients undergoing
surgical resection for malignancy (28 gastric, 23 colorectal). Using a competitive displacement assay, specific '251-tyrosine -1 -somatostatin-14 binding to plasma membranes was assessed and characterised in terms of
receptor affinity (Kd) and maximum binding capacity (Bmax) as determined by Scatchard analysis. Specific
low affinity (Kd = 166 nM), high capacity (Bmax = 1.2 pmol mg-' protein) somatostatin binding was demon-
strated in 22 of the gastric cancers and 17 of the colorectal cancers (Kd = 140nm, Bmax = 1.8 pmol mg-' protein). Similar affinity and binding capacity was demonstrable in normal mucosal samples. High affinity
receptors for somatostatin were expressed by one gastric carcinoma (Kd = 0.9 nM; Bmax = 0.23pmol mg-'
protein). Thus, low affinity, high capacity binding is a common feature ofgastrointestinal tumours and normal
mucosa, and high affinity receptors may occasionally be demonstrated. The functional significance of these low
affinity binding sites requires elucidation to determine whether long-acting somatostatin analogues may have
therapeutic benefit in gastrointestinal malignancy.
Hormonal manipulation, by surgical or medical methods, has
been used extensively in therapy for carcinoma of the breast,
prostate, thyroid and in certain gut endocrine tumours
(Horowitz et al., 1975; Higgins et al., 1941; Crile, 1957; Osei
et al., 1985). There is, however, no currently defined role for
endocrine therapy in non-endocrine gastrointestinal cancer.
Surgical intervention is the most effective treatment for this
condition and, even then, can only afford a 'cure' in early
disease. Advanced tumours are associated with a poor prog-
nosis, marginally improved by chemotherapeutic regimens.
Any benefit from systemic therapy is usually abrogated by
systemic toxicity (Rake et al., 1979; Engstrom et al., 1985;
Bleiberg, 1990). For this reason a non-toxic, effective, treat-
ment modality would be of value to improve the outlook for
those patients with advanced disease.
There is increasing evidence that tumours arising from the
gastrointestinal tract are, at least in part, hormone depen-
dent. Numerous hormones have now been implicated in the
pathogenesis and development of gastrointestinal malig-
nancy, including gastrin, epidermal growth factor, entero-
pancreatic hormones and oestrogenic steroids (Sirinek et al.,
1985; Watson et al., 1988; Li et al., 1980; Howatson &
Carter, 1985; McMichael et al., 1980). These findings,
together with the observation that transformed gut epithelial
cells may retain functional hormone receptors (Townsend et
al., 1986), have suggested a role for hormonal manipulation
in these malignancies.
Somatostatin and its analogues are good candidates for
use as endocrine agents in the treatment of gastrointestinal
cancer. The native peptide is widely distributed in the body
and, amongst its many inhibitory actions, has a putative role
as an anti-proliferative agent in both normal (Lehy et al.,
1979) and malignant (Singh et al., 1986) tissue. The
mechanisms involved in this anti-proliferative action have
not, as yet, been confirmed. Both the native peptide and its
analogues act at the somatotrophs of the anterior pituitary
suppressing growth hormone production and release (Adrian
et al., 1981). This may influence the proliferation of target
tissues directly or may result in a substantial reduction in
local growth factor release (Kirkegaard et al., 1984). Further,
the production of other trophic hormones such as gastrin
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and insulin, either from normal cells or from hormonally
active tumour cells, could be suppressed by somatostatin
(Morris et al., 1988). The most interesting mechanism, how-
ever, involves the interaction of the peptide with specific
membrane bound receptors upon proliferating cells. Certain
tumours are known to express somatostatin receptors, and
these include meningioma, carcinoid and related gut endo-
crine tumours, small cell carcinoma of the lung and growth
hormone-secreting pituitary adenomas (Reubi et al., 1987a;
Reubi et al., 1987b; Reubi et al., 1990; Ikuyama et al., 1985).
Somatostatin binding has not been investigated in human
gastrointestinal cancer. The aim of this study, therefore, was
to determine whether there was specific binding of somato-
statin to malignant gastrointestinal tissue and adjacent un-
involved mucosa, and to characterise any such binding. This
information may help determine whether somatostatin and
its analogues have a role in gastrointestinal cancer.
Patients, materials and methods
Collection and storage ofnormal andmalignant tissue
Tumour tissue and uninvolved mucosa were obtained at
operation from 51 consecutive patients (26 male, 25 female;
mean age (range) 70.4 (42-86) years) with gastrointestinal
cancer. Twenty eight of these patients suffered from gastric
cancer and the remaining 23 were operated upon for colonic
or rectal cancer. Resected specimens were opened and
washed in cold 0.9% saline immediately after surgical
removal. Incisional biopsies of macroscopically viable
tumour were removed and adjacent blocks processed for
routine histopathology. Macroscopically normal mucosa
from a site distant from the tumour was carefully dissected
from the underlying muscular layers. Tumour and normal
mucosal samples were finely divided, snap frozen in liquid
nitrogen and stored at - 70°C until assayed.
Preparation ofplasma membranes
Plasma membranes were prepared using a modification of the
method of Srikant and Patel (1981). In brief, frozen tumour
and mucosal samples were mechanically pulverised and
homogenised on ice in homogenising buffer (sucrose 250 mM,
KCI 25 mM and MgCl2 10 mM in Tris-HCI 50 mM; pH 7.4) at
10,000 r.p.m. in short bursts for 2 min using an Ultraturrax
T25 homogeniser (Scientific Instruments Ltd, Liverpool,
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UK). The homogenate was centrifuged at 4°C at 270 g for
10 min to remove nuclear debris and the supernatant
retained. This crude membrane suspension was then ultracen-
trifuged at 4°C for Omin at 15,000 g using a Beckmann L5
65B Ultracentrifuge (Beckmann Laboratory Instruments,
High Wycombe, Bucks, UK). The pellet was resuspended in
Tris-HCl buffer (Tris-HCl 10 mM, pH 7.4) and ultracent-
rifuged for Omin at 15,000g. The final pellet was
resuspended in 2 ml of the Tris-HCl buffer, pH 7.4, and the
protein content determined after the method of Bradford
(1976).
Rat cerebral cortex was used as a positive control for all
binding assays. Six week old female Wistar rats were
sacrificed by cervical dislocation and the cerebral hemispheres
dissected from the remaining cranial contents. Plasma memb-
ranes were prepared as outlined above and used at a final
protein concentration of 0.2 mg ml-'.
Preparation of'25I-tyr-J -somatostatin-14
Iodination of tyr-11-somatostatin-14 (Sigma Ltd, UK) was
performed using the Chloramine T method (Czernick & Pet-
rack, 1983). The iodination reaction mixture was eluted on a
G-25 Superfine Sephadex column using an elution buffer of
0.1 M acetic acid containing mg ml-' bovine serum
albumin. Eluted fractions were collected and the specific
activity of the combined '25I-tyr-l 1-somatostatin-14 peak was
calculated to be between 330 and 500Cimmol-1.
Demonstration ofsomatostatin binding
A twelve point competitive displacement assay was developed
and validated using plasma membranes prepared from rat
cerebral cortex. Incubation buffer (HEPES3-KOH 50 mM,
MgCl2 10 mM, BSA 1% and bacitracin 0.01%; pH 7.4),
50 ,ul, was added to each reaction tube. Unlabelled
somatostatin-14 (Sigma Ltd, UK) was then added in 10
aliquots over the concentration range 10-1 M to 10- M.
Total binding was assessed by the addition of 10 tlI of 50 mM
HEPES-KOH pH 7.4. An aliquot of 20 tlI of plasma memb-
rane preparation at a protein concentration of 1-1.5
mg ml-' was added to the reaction tubes. Finally 20 ,ul
(100,000 c.p.m.) of radioisotope (approx 2 nM) was added to
each tube. Samples were incubated for 1 h at 35°C, the
reaction being stopped by the addition of 0.5 ml ice cold
saline, and centrifugation at 13,000 g for 2 min in a Micro-
centaur microcentrifuge (MSE Ltd, UK). The supernatant
was removed by suction, the pellet washed once with 0.5 ml
ice cold saline and counted in the reaction tube on a Packard
Cobra II Autogammacounter (Canberra Packard, Pang-
bourne, Berks, UK). All assay points were performed in
triplicate and the coefficient of variation of the triplicates was
less than 10%.
Tumour site, stage and histological grade
The tumour site, stage and histological grade were assessed
by routine pathological methods by one histopathologist. The
degree of differentiation (Well, Moderate or Poor) of the
tumour was determined from the block of tissue adjacent to
that used in the binding studies. Staging of colonic/rectal
carcinoma was performed according to Dukes' classification
into stage A, B or C. Gastric adenocarcinoma was staged
according to the TNM classification and patients allocated to
Stage I-IV (after Fielding et al., 1983).
Data analysis and statistical methods
Binding data was processed using the Ligand PC Curve
Fitting Program (Munson & Rodbard, 1980) to derive
receptor affinity, Kd (nM) and maximum binding capacity
(receptor density), Bmax, expressed in terms for the protein
concentration of the membrane preparation. Data was
analysed using non parametric statistical tests of unpaired
data and all values are expressed as median (quartiles) unless
otherwise stated.
Results
Somatostatin binding in rat cerebral cortex
Binding of '25I-tyr-lI-somatostatin-14 to plasma membrane
preparations was found to be dependent upon incubation
temperature and duration. Maximal binding occurred after
35 min and remained constant until 120 min (data not
shown). Although binding characteristics at 21°C (room
temperature) and 35°C were similar, 20-30% higher specific
bound counts were observed at the higher temperature. In
view of these data, subsequent experiments were performed
with a 60 min incubation period at 35°C.
A linear relationship was found between plasma membrane
protein concentration and '25I-tyr-1 1-somatostatin binding
over the protein range 10-200,g membrane protein in a
total reaction volume of lOO1l (0.1-2.0mgml-1). Plasma
membranes were routinely assayed at a protein concentration
of 0.2-0.5 mg ml '.
Scatchard analysis of binding to rat cerebral cortex
revealed a single class ofspecific high affinity receptors with a
median (range) receptor affinity of 0.85 (0.55-0.99) nm and a
Bmax of 0.22 (0.12-0.32 pmol mg-' protein (Figure 1).
These findings are consistent with those reported previously
(Srikant & Patel, 1981; Reubi & Maurer, 1986).
Somatostatin binding in gastrointestinal tumours and normal
mucosa
Specific somatostatin binding sites were characterised in 23
out of 28 gastric cancers, 17 out of 23 colonic cancers, 21 out
of 28 samples of gastric body mucosa and in 15 out of 23
samples of colonic mucosa. In the remaining tissue specimens
there was insufficient displaceable somatostatin binding for
Scatchard analysis.
In human gastric adenocarcinoma, 22 of 28 tumours
exhibited specific low affinity binding of '251-tyr-l1-somato-
statin-14, with an affinity of 170 (72-250) nM and a Bmax of
1.2 (0.7-5.7) pmol mg-' protein. A typical displacement
curve with Scatchard plot is presented in Figure 2. In one
additional patient, high affinity receptors were demonstrated
with a Kd of 0.9 nM and Bmax of 0.23 pmolmg-' protein.
Further detailed histochemical analysis of this tumour
revealed that this was a typical gastric adenocarcinoma with
no features to suggest a neuroendocrine origin. Specifically,
staining for neurone-specific enolase, protein gene product
9.5 and chromogranin were negative.
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Figure 1 Displacement of '25I-tyr-l l-somatostatin-14 from rat
cerebral cortex membranes by somatostatin-14. Results shown
are from a single representative experiment. IC50 value was
estimated to be 1.1 nm. Inset. Scatchard plot (Bound/Free against
Bound, Bound as pmolmg-' protein, Free as nM) of the dis-
placement data as calculated by LIGAND (26), with a Kd of
0.92 nm and a Bmax of 0.21 pmol mg-' protein.SOMATOSTATIN BINDING IN GASTROINTESTINAL CANCER 393
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Figure 2 Displacement of 1251-tyr-11-somatostatin-14 from hu-
man gastric adenocarcinoma membranes by somatostatin-14.
Results shown are from a single representative experiment. IC50
value was estimated to be 158nM. Inset. Scatchard plot as in
Figure 1, revealing a site with a Kd of 165 nM and a Bmax of
6.1 pmol mg- protein.
In colorectal adenocarcinoma, 17 of 23 of plasma mem-
brane preparations exhibited low affinity, high capacity bin-
ding with a Kd of 140 (89-200) nM and Bmax of 1.8
(1.2-2.9) pmol mg-' protein.
Low affinity, high capacity binding was demonstrable in 21
of 28 gastric body mucosal plasma membrane preparations,
including the sample from the patient whose tumour
exhibited high affinity binding, with a Kd of 180
(81-270) nM and Bmax of 3.9 (1.2-6.6) pmol mg-' protein.
These values are not significantly different from those found
in the gastric carcinoma tissue.
In normal colonic mucosa, specific somatostatin binding of
similar affinity and receptor density (Kd of 130 (71-200) nM;
Bmax of 0.7 (0.3-3.5) pmol mg'- protein) to that in the
stomach was demonstrated in 15 of 23 plasma membrane
preparations. There were no statistically significant
differences in receptor characteristics between normal and
malignant colorectal samples.
Relationship between binding characteristics and tumour site,
stage andgrade
Details of the tumours' site, grade and stage are shown in
Table I, along with the binding characteristics. There was no
relationship between any of the tumour characteristics and
somatostatin binding.
Discussion
The current report represents the first systematic examination
of somatostatin binding in solid neoplasms of the gastrointes-
tinal tract. We have demonstrated high levels of specific
binding for this peptide in membrane preparations from the
majority of human colorectal and gastric cancers, and that
these binding sites are also present in normal mucosa. The
binding in both malignant tissue and uninvolved mucosa is
normally low affinity, with a Kd usually in the micromolar
range, in contrast to the high affinity binding site we demon-
strate in rat cerebral cortex. One gastric tumour, however, in
repeated determinations, consistently exhibited a high affinity
binding site indicating that this tissue expresses a different
class of receptor. Interestingly, the binding in the adjacent
normal mucosa in this patient was of the normal, low
affinity, type which we characteristically demonstrate in
mucosa.
The demonstration of low affinity binding in normal gas-
tric mucosa may seem at variance with reports of somato-
statin binding in isolated parietal cell preparations (Sjodin et
al., 1990; Reyl-Desmars & Lewin, 1982), although species
variations and differences in ligand (Conlon et al., 1981)
make comparisons difficult. However, it is possible that high
Table I Somatostatin binding in colorectal and gastric cancer tissue
n Bmax (pmol
+ ve Kd (nM) mg''protein)
Colo-rectal Site
Cancer - Rectum 8/12 112 (71 -180) 1.67 (1.02-2.78)
- Sigmoid 3/5 161 (10- 181) 0.49 (0.11 -1.75)
- (L) Colon 0/1 / /
- (R) Colon 5/5 140 (97-200) 2.99 (2.12-3.94)
Stage
- A 1/1 300 3.40
- B 7/11 89 (53-200) 1.72 (1.30-2.99)
- C 8/11 143 (104-171) 1.48 (0.62-2.41)
Grade
- Well 5/8 161 (84-181) 1.75 (0.49-2.99)
- Mod 9/12 113 (89-145) 1.72 (1.30-2.69)
- Poor 2/3 163 (111-215) 1.81 (0.74-2.87)
Gastric Site
Cancer - Body 10/11 78 (45-185) 0.83 (0.25-7.43)
- Antrum 10/12 165 (78-169) 1.04 (0.67-3.36)
- Cardia 5/5 265 (236-293) 1.73 (1.23-5.11)
Stage
- I 1/2 89.2 0.28
- II 6/6 78 (67-165) 0.79 (0.23-1.04)
-III 17/19 168 (73-265) 1.24 (0.77-6.11)
- IV 1/1 169 6.3
Grade
- Well 1/3 265 5.11
- Mod 17/7 165 (67-298) 1.04 (0.23-6.23)
- Poor 17/18 162 (73-185) 1.17 (0.67-5.71)
The data from 23 patients with colorectal cancer and 28 with gastric cancer
are demonstrated. 'n' refers to the number of samples in which there was
sufficient displaceable binding to allow Scatchard analysis. The Kd (receptor
affinity) and Bmax (total numberofbindingsites) are shown foreach site, stage
and grade of tumour.394 G.V. MILLER et al.
affinity binding, which may be found in certain cell popula-
tion in the mucosa, is not being detected by our technique
which employs a whole tissue membrane preparation. It is of
interest that Reubi and Maurer (1986) have demonstrated a
low affinity receptor site in rat cerebral cortex, although this
'low affinity' site has a much higher affinity than that which
we have identified.
In many receptor binding systems, it is assumed that func-
tioning receptors require high ligand affinity such that
optimum binding can occur at physiological hormone con-
centrations. That only one tumour of 51 assayed should
express such high affinity receptor sites for somatostatin may
seem disappointing since it implies that therapy based upon
long-acting somatostatin analogues may be of benefit in a
very small minority of patients. The incidence of high affinity
receptors for other hormones, such as gastrin, in colonic
carcinoma has been reported as 50-60% (Upp et al., 1989).
Thus, gastrin antagonist therapy may be a reasonable
therapeutic modality in receptor positive cases. However, the
physiological and functional significance of such low affinity
somatostatin binding is less easily evaluated.
One possible explanation for the function of a low affinity
receptor is that it may be involved in local regulation, in an
autocrine or paracrine fashion, as opposed to a true endo-
crine mechanism. Low circulating levels of somatostatin may
be functionally insignificant whilst high local levels within the
mucosa/tumour may be active. These findings are of impor-
tance if therapy based on the natural anti-proliferative effects
of somatostatin is to be considered. Clearly, the native pep-
tide cannot be used as a pharmacologically useful agent since
its half life in the circulation is less than 3 min. However,
current analogues of somatostatin, which are based upon a
cyclic octapeptide sequence, have been found to have
100-200 times the suppressive effect on growth hormone
release of native somatostatin with biological half lives of
3-6 h (Cai et al., 1986). Thus, used in pharmacological
doses, appropriately designed analogues may be expected to
have significant effects on low affinity receptors.
The results of our studies do not directly tell us whether
somatostatin analogues will be of value in gastrointestinal
cancer since firstly, the functional significance of the binding
we have demonstrated is not clear and, secondly, somato-
statin may exert growth effects independently of its inter-
action with membrane bound receptors on tumour cells. The
direct, receptor mediated effects of somatostatin on cell
growth appear to relate to the dephosphorylation of intra-
cellular phosphoproteins (Reyl & Lewin, 1982). It is known
that EGF stimulates cell growth by inducing phosphorylation
of these residues and, as a corollary, somatostatin induced
dephosphorylation has been suggested to correlate with
inhibition of EGF stimulated cell growth in certain cancer
cell lines (Liebow et al., 1989; Hierowski et al., 1985). Fur-
ther studies, including examination of second messenger
activation and affinity labelling may elucidate the therapeutic
potential of the interaction between somatostatin and low
affinity binding sites in human gastrointestinal cancer.
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